Showing results (91-100 of 11,855) with videos related to
Sort By:
Pageof 1,186
Neuron|August 19, 2007
Contributions of the amygdala to reward expectancy and choice signals in human prefrontal cortexAlan N Hampton, Ralph Adolphs, Michael J Tyszka, et al.The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 22, 2011
Intact bilateral resting-state networks in the absence of the corpus callosumJ Michael Tyszka, Daniel P Kennedy, Ralph Adolphs, et al.Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|January 11, 2019
Activity of Ceftolozane/Tazobactam Against Gram-Negative Rods of the Family Enterobacteriaceae and Pseudomonas Spp. Isolated from Onco-Hematological Patients Hospitalized in a Clinical Hospital in PolandOlga Saran, Beata Sulik-Tyszka, Grzegorz W Basak, et al.Brain and Cognition|June 1, 1996
Homogeneity of effect sizes for sex across spatial tests and cultures: implications for hormonal theoriesI Silverman, K Phillips, L K SilvermanInternational Journal of Occupational and Environmental Health|July 1, 1997
Shift-related Differeces in Industrial Injuries: Application of a New Research Method in Fixed-shift and Rotating-shift SystemsSmith, Silverman, Heckert, et al.Journal of Medicinal Food|August 21, 2013
Rutabaga (Brassica napus L. var. napobrassica) seeds, roots, and sprouts: a novel kind of food with antioxidant properties and proapoptotic potential in Hep G2 hepatoma cell linePawel Pasko, Karolina Bukowska-Strakova, Joanna Gdula-Argasinska, et al.Cerebral Cortex (New York, N.Y. : 1991)|February 22, 2013
Largely typical patterns of resting-state functional connectivity in high-functioning adults with autismJ Michael Tyszka, Daniel P Kennedy, Lynn K Paul, et al.JACC. Case Reports|July 4, 2025
Prosthetic Mitral Valve Fungal Endocarditis: Challenges in Diagnosis and ManagementAndré L Tyszka, Maria Emilia A Machado, Harissa S El Ghoz, et al.Biotechnology Healthcare|April 6, 2012
Setting the Bar Higher For Off-Label Use of Biologics: Off-label use of biologics is common as physicians strive for optimal treatment. Patients want whatever works. Drug makers want expanded labeling, but payers chafe at the lack of efficacy data. Is there an answer to this conundrum?Ed SilvermanBiotechnology Healthcare|April 6, 2012
Creating a pathway over the regulatory chasm: a fresh startEd SilvermanPageof 1,186